IL222930B - Chlorotoxin variants, conjugates and methods for their use - Google Patents

Chlorotoxin variants, conjugates and methods for their use

Info

Publication number
IL222930B
IL222930B IL222930A IL22293012A IL222930B IL 222930 B IL222930 B IL 222930B IL 222930 A IL222930 A IL 222930A IL 22293012 A IL22293012 A IL 22293012A IL 222930 B IL222930 B IL 222930B
Authority
IL
Israel
Prior art keywords
conjugates
methods
chlorotoxin variants
chlorotoxin
variants
Prior art date
Application number
IL222930A
Other languages
English (en)
Hebrew (he)
Other versions
IL222930A0 (en
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of IL222930A0 publication Critical patent/IL222930A0/en
Publication of IL222930B publication Critical patent/IL222930B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • G01N33/575
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
IL222930A 2010-05-11 2012-11-08 Chlorotoxin variants, conjugates and methods for their use IL222930B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33355610P 2010-05-11 2010-05-11
PCT/US2011/023797 WO2011142858A2 (en) 2010-05-11 2011-02-04 Chlorotoxin variants, conjugates, and methods for their use

Publications (2)

Publication Number Publication Date
IL222930A0 IL222930A0 (en) 2012-12-31
IL222930B true IL222930B (en) 2019-01-31

Family

ID=44914898

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222930A IL222930B (en) 2010-05-11 2012-11-08 Chlorotoxin variants, conjugates and methods for their use

Country Status (10)

Country Link
US (2) US9944683B2 (enExample)
EP (2) EP3165533B1 (enExample)
JP (2) JP2013532126A (enExample)
KR (1) KR101972173B1 (enExample)
CN (2) CN106957356B (enExample)
AU (1) AU2011253424B2 (enExample)
CA (1) CA2799169C (enExample)
ES (2) ES2811065T3 (enExample)
IL (1) IL222930B (enExample)
WO (1) WO2011142858A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
CA2749108C (en) 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
WO2011097533A1 (en) * 2010-02-04 2011-08-11 Transmolecular, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
CN102688496B (zh) * 2012-01-15 2013-12-11 河南科技大学 一种ctx介导的靶向纳米载体及纳米载药体系
SG11201504602VA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Lipocalin fusion partners
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
AU2014323563B9 (en) * 2013-09-17 2019-10-24 Blaze Bioscience, Inc. Chlorotoxin conjugates and methods of use thereof
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6741599B2 (ja) 2014-06-02 2020-08-19 リ−コール,インコーポレイティド フタロシアニンプローブ及びその使用
US20180371033A1 (en) * 2015-06-26 2018-12-27 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
CN108135970B (zh) 2015-09-09 2023-09-01 弗莱德哈钦森癌症中心 软骨归巢肽
MA44386A (fr) * 2015-10-07 2019-01-23 Genentech Inc Systèmes et méthodes de prédiction de demi-vie vitréenne de conjugués d'agent thérapeutique et de polymère
US20190161523A1 (en) 2016-04-12 2019-05-30 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
US11878000B2 (en) * 2016-10-21 2024-01-23 Da Zen Theranostics, Inc. Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
WO2018086603A1 (zh) * 2016-11-10 2018-05-17 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
IL266892B2 (en) 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
JP7191025B2 (ja) 2017-01-18 2022-12-16 フレッド ハッチンソン キャンサー センター Tead相互作用を妨害するためのペプチド組成物およびその使用方法
AU2018236465A1 (en) 2017-03-16 2019-08-22 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
CA3064436A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
CN111542345B (zh) 2017-09-15 2025-02-25 卫材公司 氯毒素剂及其用途
WO2019126240A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
AU2020407558A1 (en) * 2019-12-19 2022-03-17 Blaze Bioscience, Inc. Methods of treating vascular lesions and malformations
AU2021412432B2 (en) 2020-12-30 2024-11-14 Vrg Miniprotein Zrt. Chlorotoxin derivatives and use thereof

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3407582A1 (de) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen Schaltungsanordnung fuer einen regelkreis
EP0282581A4 (en) 1986-09-19 1988-11-02 Scripps Clinic Res Monoclonal paratopic molecule directed to human ganglioside gd2.
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
GB2250993B (en) 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
ES2225819T3 (es) 1991-09-20 2005-03-16 Amgen Inc. Factor neurotrofico de origen glial.
US5314992A (en) 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
AU4373993A (en) 1992-05-14 1993-12-13 Ohio State University Research Foundation, The Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
IL108328A (en) 1993-01-14 2010-05-31 Cancer Res Campaign Tech Pharmaceutical compositions containing temozolomide and atase inhibitor for potentiation of temozolomide toxicity to human tumor cells
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス(cav)感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
CN1284083A (zh) 1997-12-05 2001-02-14 伊东恭悟 肿瘤抗原肽衍生物
GB9809776D0 (en) 1998-05-07 1998-07-08 Nycomed Imaging As Method
ATE279411T1 (de) * 1998-08-12 2004-10-15 Daiichi Pure Chemicals Co Ltd Fluorszierende marker
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1216060A2 (de) 1999-09-14 2002-06-26 Biomedical Apherese Systeme GmbH Magnetische nanoteilchen mit biochemischer wirksamkeit und verfahren zu ihrer herstellung sowie ihre verwendung
US6514481B1 (en) 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
DE10020376A1 (de) 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20020077921A1 (en) 2000-12-15 2002-06-20 Paul-David Morrison Method and apparatus for an interactive catalog
US20040180846A1 (en) 2001-03-01 2004-09-16 Ruo-Pan Huang Connexin enhances chemotherapy-induced apoptiosis in human cancer cells inhibiting tumor cell proliferation
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20030021810A1 (en) 2001-06-26 2003-01-30 Sontheimer Harald W. Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
WO2003066663A2 (en) 2002-02-04 2003-08-14 Auburn University Peptides for recognition and targeting of glial cell tumors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
EP1539207A4 (en) 2002-05-31 2008-01-02 Transmolecular Inc TREATMENT OF CELL PROLIFERATION DISORDERS USING CHLOROTOXIN
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DE10328251A1 (de) 2003-06-24 2005-01-13 Toximed Gmbh Pharmazeutischer Wirkstoff
US20070275902A1 (en) 2003-11-26 2007-11-29 Transmolecular, Inc. Treatment of Phosphatidylinositol Phospholipid Disorders
US20080153746A1 (en) * 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
CA2561494A1 (en) 2004-04-06 2005-10-27 Transmolecular, Inc. Diagnosis and treatment of myeloid and lymphoid cell cancers
WO2005107793A2 (en) 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
GB0422901D0 (en) 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
EP2147927A3 (en) 2006-03-31 2010-09-01 Transmolecular, Inc. Use of 131i-tm-601 for the diagnosis and treatment of gliomas
EP2029157A4 (en) 2006-05-19 2009-11-18 Georgia Tech Res Inst ABC TRANSPORTERLIGAND
CN100564517C (zh) 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
CN101003788A (zh) 2006-09-21 2007-07-25 武汉大学 一种蝎抗肿瘤转移肽及其制备方法和应用
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
CN101970678B (zh) 2007-06-21 2014-08-20 慕尼黑科技大学 具有增加的体内和/或体外稳定性的生物学活性蛋白
US20090004105A1 (en) * 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
WO2009021136A1 (en) 2007-08-07 2009-02-12 Transmolecular, Inc. Chlorotoxins as drug carriers
WO2009029760A1 (en) 2007-08-31 2009-03-05 Iosemantics, Llc Quality assurance tools for use with source code and a semantic model
CN101918041A (zh) 2007-10-12 2010-12-15 超分子有限公司 用于肿瘤诊断和治疗的氯毒素剂的系统性给药
US7904868B2 (en) 2007-10-17 2011-03-08 International Business Machines Corporation Structures including means for lateral current carrying capability improvement in semiconductor devices
US20090124022A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090176274A1 (en) 2007-10-19 2009-07-09 Abbott Laboratories Glycosylated mammalian ngal and use thereof
WO2009052400A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090123970A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
EP2215481B2 (en) 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
CA2749108C (en) * 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
WO2009108762A2 (en) 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8093060B2 (en) * 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
CA2715034C (en) * 2008-03-14 2016-12-06 Visen Medical, Inc. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
AU2008352925A1 (en) 2008-03-20 2009-09-24 Transmolecular, Inc. Inhibition of angiogenesis
GB0807831D0 (en) * 2008-04-29 2008-06-04 Cambridge Entpr Ltd Agents for imaging cell death
CN101270158B (zh) 2008-04-30 2010-12-22 武汉大学 一种靶向抗神经胶质瘤蛋白及制备方法和用途
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
JP2009300110A (ja) * 2008-06-10 2009-12-24 Olympus Corp 移植細胞の光学的検出方法又はイメージング方法
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
AR073582A1 (es) * 2008-09-12 2010-11-17 Nitto Denko Corp Agentes de produccion de imagenes de enfermedades fibroticas.conjugado. metodo
US20100098637A1 (en) * 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (zh) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 基因工程肿瘤靶向kct-w1多肽及制备方法和用途
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
CN106519588B (zh) 2009-11-09 2019-08-20 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
CN101921769B (zh) 2010-01-11 2012-07-25 山西大学 一种重组腺病毒及其制备方法和应用
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
WO2011097533A1 (en) 2010-02-04 2011-08-11 Transmolecular, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
CN101824084A (zh) 2010-04-08 2010-09-08 山西大学 靶向性抗胶质瘤蛋白质及其应用
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
SG11201504602VA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Lipocalin fusion partners
WO2017181149A1 (en) * 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
EP3442555A4 (en) * 2016-04-15 2020-04-01 Blaze Bioscience, Inc. METHOD FOR TREATING BREAST CANCER

Also Published As

Publication number Publication date
US10822381B2 (en) 2020-11-03
CA2799169C (en) 2019-07-23
KR20130113938A (ko) 2013-10-16
US9944683B2 (en) 2018-04-17
ES2811065T3 (es) 2021-03-10
EP2569330A4 (en) 2013-11-13
CN103097403A (zh) 2013-05-08
AU2011253424A1 (en) 2012-12-20
WO2011142858A9 (en) 2012-03-22
CN106957356B (zh) 2021-05-25
WO2011142858A3 (en) 2012-01-05
JP2013532126A (ja) 2013-08-15
EP3165533B1 (en) 2020-04-08
ES2601182T3 (es) 2017-02-14
US20180194818A1 (en) 2018-07-12
JP6553105B2 (ja) 2019-07-31
CA2799169A1 (en) 2011-11-17
IL222930A0 (en) 2012-12-31
EP2569330A2 (en) 2013-03-20
CN106957356A (zh) 2017-07-18
KR101972173B1 (ko) 2019-04-24
EP2569330B1 (en) 2016-09-28
WO2011142858A2 (en) 2011-11-17
EP3165533A1 (en) 2017-05-10
CN103097403B (zh) 2017-04-19
AU2011253424B2 (en) 2016-02-04
US20130195760A1 (en) 2013-08-01
JP2017137316A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
IL222930B (en) Chlorotoxin variants, conjugates and methods for their use
IL243932A0 (en) Certain chemical entities, compositions and methods
BR112014009050A2 (pt) pirrolbenzodiazepinas e conjugados destas
BR112013010725A2 (pt) método, e, composição
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
DK3103478T3 (da) Stabiliserede fibronektin-domænesammensætninger, fremgangsmåder og anvendelser
ME03766B (me) Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
BR112012017441A2 (pt) compostos e métodos
BR112013013584A2 (pt) endoscópio, e, método
IL226307A0 (en) Compounds and methods for treating pain
HRP20150926T4 (hr) Pripravci u krutom stanju
ME03479B (me) Metodi konjugacije
PL2648726T3 (pl) Policykliczny antagonista lpa1 i jego zastosowania
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
PT3686183T (pt) Fenilacetato de l-ornitina e métodos de preparação do mesmo
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
EP2531206A4 (en) CHLOROTOXINPOLYPEPTIDES AND CONJUGATES AND USES THEREOF
BR112012027159A2 (pt) estrutura e método
IL226427A0 (en) Anti ccr4 antibodies and uses thereof
BR112012019626A2 (pt) estrutura de plantio e métodos.
FI20096339L (fi) Liima-aine, menetelmä sen valmistamiseksi sekä sen käyttö
EP2647648A4 (en) hydroxyalkylcellulose
IT1398438B1 (it) Dispositivo di premacinazione e relativo procedimento
HRP20170691T1 (hr) Polimerni konjugati djelatnih tvari, njihov postupak dobivanja i njihovi polimerni intermedijeri

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed